The Study Of Meloxicam On Clinical Safety And Curative Effect Of Induced Osteoarthritis In Dogs

Meloxicam is a new non-steroidal anti-inflammatory drug in the oxicam family. Since the selective inhibition of cyclooxygenase-2, meloxicam conducts a perfect effect of anti-inflammatory in animal experiments and clinical studies. In our studies, experimental dogs were provided for studying the clinical hematology, blood biochemistry and histopathology, which supplied for the safely clinical data. In addition, the present study also evaluated the effect of anti-inflammatory of meloxicam in dogs clinically, which provided a scientific basis for application.Test I Clinical safety of meloxicam in dogsThe test was conducted to evaluate the clinical safety of meloxicam in dogs. Twenty-four healthy adult dogs, male and female half-half, were randomly divided into four groups contained with six. Based on the recommended clinical dose of the drug (0.1mg·kg-1), experimental treatments were followed:the control group (0mg·kg-1), the recommended clinical dose group (0.1mg·kg-1),3times clinical dose group (0.3mg·kg-1),5times clinical dose group (0.5mg·kg-1). The dogs were administered for dugs once daily, which continuously administrated for28d. Clinical symptoms of dogs were carefully observed through the whole trial. On d1,7,14,21and28(after drug administration), the safety evaluations of meloxicam were compared with the results of blood pharmacokinetic indicators and histopathology. The results showed that:the recommended clinical dose (0.1mg·kg-1) of meloxicam is safe in dogs for28d.Text II Clinical efficacy of meloxicam in a canine osteoarthritis modelThe aim of this study was to evaluate the anti-inflammatory effect of meloxicam in dogs. Eighteen healthy adult dogs were selected and induced to the models of canine osteoarthritis resected cruciate ligament and medial meniscus in the knee. Animal models were fed with meloxicam and tepoxalin in reasonable recommended dose, once daily, which continuously administrated for14d. A blank control and positive control group were set. Compared with the treatment of tepoxalin, blood parameters, synovial fluid changes and clinical symptoms were verified for the clinical efficacy of meloxicam. Results showed that:there is no significance difference of blood parameters in treatment and control group before and after therapy. Significance differ were found between treatment group and positive control group on scores of clinical symptoms. In the group fed with meloxicam,0(0/6)recovery,16.7%(1/6)excellence,83.3%(5/6)advance,0(0/6) inefficiency, the total effective rate is100%(6/6). There is no significant difference with tepoxalin treatment group. Though the whole test, no drug-related adverse reactions appeared, which showed that meloxicam is also well-tolerated.